Market Risers: easyJet plc, GlaxoSmithKline plc, Glencore PLC

GlaxoSmithKline plc

The share price for easyJet plc ticker code: LON:EZJ has climbed 1.39% or 22 points in today’s trading session so far. Traders are a positive bunch while the stock has been in play. Range high for the period has seen 1612.5 and hitting a low of 1584.5. The total volume of shares exchanged through this period comes to 1,027,560 with the average number of shares traded daily being 2,004,007. A 52 week share price high is 1808.5 amounting to 230.5 points difference from the previous days close and putting the 52 week low at 1136 which is a difference of 442 points. easyJet plc now has a 20 SMA at 1717.06 and a 50 day moving average now of 1729.68. Market capitalisation is now £6,488.24m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for easyJet plc being recorded at Thursday, July 12, 2018 at 1:34:57 PM GMT with the stock price trading at 1600 GBX.

 

 

Shares of GlaxoSmithKline plc EPIC code: LON:GSK has stepped up 1.48% or 23 points in today’s trading session so far. Buyers have remained optimistic during the session. The period high has peaked at 1578.8 while the low for the session was 1556.4. Volume total for shares traded at this point reached 3,187,610 with the average number of shares traded daily being 10,051,588. The 52 week high for the shares is 1636.5 equating to 83.3 points in difference on the previous days close and a 52 week low being 1179.39 making a difference of 373.81 points. GlaxoSmithKline plc has a 20 day moving average of 1551.21 and now its 50 day simple moving average now of 1526.07. The current market capitalisation is £78,690.90m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for GlaxoSmithKline plc being recorded at Thursday, July 12, 2018 at 1:34:57 PM GMT with the stock price trading at 1576.2 GBX.

 

 

The share price for Glencore PLC with ticker code: LON:GLEN has gained 1.48% or 4.6 points throughout the session so far. Traders have remained positive throughout the session. The period high was 318.3 while the low for the session was 311.35. Volume total for shares traded at this point reached 19,722,559 whilst the average number of shares exchanged is 65,098,149. The 52 week high price for the shares is 416.91 some 105.76 points different to the previous business close and a 52 week low sitting at 303 is a variance of 8.14999999999998 points. Glencore PLC now has a 20 SMA of 364.8 and now its 50 day MA at 377.08. Market capitalisation for the company is £48,108.59m at the time of this report. The currency for this stock is GBX. Market cap is measured in GBP. This article was written with the last trade for Glencore PLC being recorded at Thursday, July 12, 2018 at 1:34:53 PM GMT with the stock price trading at 315.75 GBX.

Share on:
Find more news, interviews, share price & company profile here for:

    GSK Plc completes acquisition of IDRx, Inc.

    GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor.

    Glencore Plc appoints María Margarita Zuleta as an Independent Non-Executive Director

    Glencore plc appoints María Margarita Zuleta as Independent Non-Executive Director, enhancing board expertise with her legal and governance experience.

    GSK Plc 5-in-1 meningococcal vaccine approved by FDA

    GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates.

    GSK Plc reports strong growth in Specialty Medicines and R&D progress

    GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns.

    GSK plc Depemokimab applications accepted for review in China and Japan

    GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results.

    GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

    GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe.

      Search

      Search